Stockwinners Market Radar for February 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:40 EST Ligand's partner Travere Therapeutics gets FDA accelerated approval of Filspari - Ligand Pharmaceuticals (LGND) announced that its partner Travere Therapeutics (TVTX) has received accelerated approval from the U.S. FDA for Filspari to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio greater than or equal to1.5 g/g. Ligand is entitled to receive a net $15.3M milestone and net royalties of 9% on future sales.

17:43 EST Lockheed Martin awarded $1.1B initial contract from U.S. Navy - Lockheed Martin is partnering with the U.S. Navy to integrate hypersonic strike capability onto surface ships. The U.S. Navy awarded Lockheed Martin a contract worth more than $2B, if all options are exercised, to integrate the Conventional Prompt Strike, CPS, weapon system onto ZUMWALT-class guided missile destroyers, DDGs. CPS is a hypersonic boost-glide weapon system that enables long range missile flight at speeds greater than Mach 5, with high survivability against enemy defenses. Under this contract, prime contractor Lockheed Martin will provide launcher systems, weapon control, All Up Rounds, or AURs, which are the integrated missile components, and platform integration support for this naval platform. The company, along with industry partners including subcontractors Northrop Grumman and General Dynamics Mission Systems, is on track to provide the CPS surface-launched, sea-based hypersonic strike capability to sailors by the mid-2020s. The contract also provides for additional AURs plus canisters for the U.S. Army's Long Range Hypersonic Weapon testing, training and tactical employment.

17:30 EST LegalZoom identifies error within income tax provision - According to a regulatory filing, LegalZoom identified an error within its income tax provision relating to the identification of named executive officers subject to limitation on the deductibility of executive compensation under Internal Revenue Code Section 162(m). As a result of this error, deferred tax assets as of March 31, 2022 were understated and the provision for income taxes for the three months then ended was overstated by $3.9M, reflecting a discrete impact of $2.4M and a $1.5M impact of the error in the annual effective tax rate. The correction of this error will reduce the company's net loss for the quarter ended March 31, 2022. As a result, on February 16, 2023, management and the Audit Committee of the Board of Directors concluded that the previously issued unaudited condensed consolidated financial statements of the company as of and for Q1 2022 included in the company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 16, 2022 were materially misstated. As a result, the quarterly financial statements included in the Q1 2022 Form 10-Q require restatement and should no longer be relied upon. In addition, any previously issued or filed earnings releases, investor presentations or other communications describing the company's quarterly financial statements and other related financial information covering Q1 2022 should no longer be relied upon. The impact of the restatement and the other immaterial revisions will reduce net loss by $4.9M for Q1 2022. The restatement of the quarterly financial statements does not impact the Company's reported cash flows or its cash position.

17:22 EST PacWest Bancorp sees 200 job cuts at Civic Financial Services - In a regulatory filing, PacWest Bancorp announced additional details regarding the restructuring of Civic Financial Services. Civic, located in Redondo Beach, California, specializes in business-purpose residential non-owner-occupied investment properties. Last month, the company announced it recorded a goodwill impairment of $29M as part of a strategy to restructure Civic to improve its profitability and risk profile. This restructuring involves reducing the number of loan products offered, reducing loan growth compared to 2022 levels, and transferring the management of most Civic functions to company executives. In addition, the company plans to provide a WARN Act notice to Civic employees next week and anticipates that approximately 200 Civic positions will be eliminated, effective in the second quarter of 2023. These position eliminations are expected to result in approximately $30M-40M of annualized savings. This restructuring aligns with the company's strategy to focus on relationship-based community banking and to improve capital, liquidity, and operational efficiency.

17:14 EST Sigma Lithium jumps 27% to $37.49 after Bloomberg reports Tesla mulls offer

17:03 EST CIBC settles Cerberus matter for $770M - CIBC announced that it has entered into an agreement with the special purpose vehicle controlled by Cerberus Capital Management L.P. to fully settle the previously disclosed lawsuit filed by Cerberus against CIBC including the most recent judgment of the New York Court. Pursuant to the settlement agreement, CIBC has agreed to pay $770M to Cerberus in full satisfaction of the judgment, and both parties have agreed to arrange for the immediate dismissal, with prejudice, of all claims, counterclaims and appeals relating to the litigation. The parties have also agreed to mutual releases in respect of the matter. The settlement also eliminates the uncertainty, distraction and expense of continued litigation between the parties. CIBC recorded a pre-tax provision of C$1.169B in its first quarter 2023 results to be released on February 24, 2023, representing damages and pre-judgment interest totaling $855M through January 31, 2023. The $85M difference between the amount recorded in the first quarter 2023 results and the settlement amount will be reflected in CIBC's second quarter results.

17:00 EST Repligen CFO Snodgres sells 5,647 common shares - In a regulatory filing, Repligen CFO Jon Snodgres disclosed the sale of 5,647 common shares of the company on February 16 at a price of $200 per share.

16:57 EST Nabors Energy Transition to extend date to consummate Vast Solar combination - Nabors Energy Transition announced that its board of directors has elected to extend the date by which NETC has to consummate a business combination by an additional three-month period from February 18 to May 18, as permitted under NETC's amended and restated certificate of incorporation. The extension provides NETC with additional time to complete its previously announced initial business combination with Vast Solar Pty. In connection with the extension, Nabors Lux 2 S.a.r.l. and Greens Road Energy, each an affiliate of Nabors Energy Transition Sponsor, have deposited a total of $2.76M, representing 10c per unit for the units sold in NETC's initial public offering, into NETC's trust account for its public stockholders, which enable NETC to effectuate the extension. Nabors Lux and Greens Road each loaned their respective portion of the extension payment to NETC through a non-interest-bearing loan. If NETC consummates an initial business combination, it will repay the loans out of the proceeds of the trust account or, at the option of the sponsor, convert all or a portion of the loans into warrants for $1.00 per warrant, which warrants will be identical to the warrants issued by NETC in a private placement in connection with NETC's initial public offering. If NETC does not consummate an initial business combination, it will repay the loans only from funds held outside the trust account.

16:47 EST Imperial Petroleum to acquire two handysize drybulk carriers built in Japan - Imperial Petroleum announced that it has entered into agreements to acquire two handysize drybulk carriers, built in Japan at Nakai Zosen in 2012 and at Shin Kurushima Onishi in 2013 respectively, with an aggregate capacity of approximately 71,000 dwt, from entities affiliated with our CEO, for aggregate cash consideration of $25.5M and 13,875 shares of Series C Cumulative Convertible Perpetual Preferred Stock. Delivery of the vessels on a charter-free basis, and closing of the transactions, is expected by the end of.

16:36 EST ElectraMeccanica to recall approximately 428 Solo or G3 vehicles - ElectraMeccanica announced it will voluntarily recall approximately 428 Solo, or G3, vehicles, model years 2021, 2022 and 2023. While driving, the vehicle may experience a loss of propulsion. An instrument cluster warning light illuminates, and the driver will experience a loss of power as the vehicle decelerates as if removing their foot from the accelerator pedal. Steering, braking, and lighting systems are not impacted. The vehicle can be restarted after a short period of time. In the event of sudden loss of propulsion, the vehicle maintains all other critical functionality including power steering, braking, and lighting, and in most instances allows the driver to pull over. However, due to the unexpected loss of propulsion, there may be an increased risk of crash, albeit the company has not received any reports of injuries or crashes.

16:35 EST Travere Therapeutics trading resumes

16:32 EST FTAC Athena Acquisition to redeem public shares - FTAC Athena Acquisition Corp. announced that, because the company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association, the company intends to dissolve and liquidate in accordance with the provisions of the Charter, effective as of the close of business on February 24, and will redeem all of the outstanding Class A ordinary shares that were included in the units issued in its initial public offering, at a per-share redemption price of approximately $10.17. As of the close of business on February 24, the Public Shares will be deemed cancelled and will represent only the right to receive the redemption amount. The company anticipates that the Public Shares, as well as the company's publicly traded units and warrants, will cease trading as of the close of business on February 23.

16:31 EST TradeUp Acquisition announces extension of business combination deadline - TradeUP Acquisition Corp. announced that, in order to extend the date by which the company must complete its initial business combination from February 19, 2023 to March 19, 2023, for each public share that is not redeemed by the company's stockholders in connection with such Extension, the company has deposited into its trust account an aggregate of $45,511.00, representing 5c per public share of the company. The payment for such Monthly Extension Fee was made by Estrella Biopharma, Inc., a Delaware corporation, pursuant to the Agreement and Plan of Merger, entered by and among the company, Tradeup Merger Sub Inc., a Delaware corporation and direct, wholly owned subsidiary of UPTD, and Estrella on September 30, 2022. Pursuant to the company's current Charter, the company may extend on monthly basis from January 19, 2023 until July 19, 2023 or such an earlier date as may be determined by its board to complete a business combination by depositing the Monthly Extension Fee for each month into the Trust Account.

16:25 EST Travere Therapeutics announces FDA accelerated approval of Filspari - Travere Therapeutics announced that the FDA has granted accelerated approval to Filspari to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio greater than or equal to1.5 g/g. This indication is granted under accelerated approval based on reduction in proteinuria. It has not been established whether Filspari slows kidney function decline in patients with IgAN. The continued approval of Filspari may be contingent upon confirmation of a clinical benefit in the ongoing Phase 3 PROTECT Study, which is designed to demonstrate whether Filspari slows kidney function decline. Topline results from the two-year confirmatory endpoints in the PROTECT Study are expected in the fourth quarter of 2023 and are intended to support traditional approval of Filspari. The company expects Filspari to be available beginning the week of February 27, and will be providing a comprehensive patient support program throughout the patient's treatment journey.

16:13 EST Wintrust Financial director Kenney acquires 6,600 common shares - In a regulatory filing, Wintrust Financial director Brian Kenney disclosed the purchase of 6,600 common shares of the company on February 16 at a price of $92.23 per share.

16:08 EST Financial Institutions increases quarterly dividend 3.4% - Financial Institutions announced that its board has approved a quarterly cash dividend of 30c per outstanding common share, an increase of 1c or 3.4% from the most recent quarter. The dividend is payable April 3 to shareholders of record on March 16.

16:06 EST Travere Therapeutics announces FDA accelerated approval of FILSPARITM - Travere Therapeutics announced that the U.S. FDA has granted accelerated approval to FILSPARI to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio greater than or equal to1.5 g/g. This indication is granted under accelerated approval based on reduction in proteinuria. It has not been established whether FILSPARI slows kidney function decline in patients with IgAN. The continued approval of FILSPARI may be contingent upon confirmation of a clinical benefit in the ongoing Phase 3 PROTECT Study, which is designed to demonstrate whether FILSPARI slows kidney function decline. Topline results from the two-year confirmatory endpoints in the PROTECT Study are expected in the fourth quarter of 2023 and are intended to support traditional approval of FILSPARI. The company expects FILSPARI to be available beginning the week of February 27, and will be providing a comprehensive patient support program throughout the patient's treatment journey.

15:39 EST Mountain Crest Acquisition Corp III trading halted, volatility trading pause

15:20 EST Iveric bio rallies 23% to $24.70 after FDA approves Apellis drug

15:05 EST Apellis' Syfovre new drug application approved by FDA - A letter posted to the site of the FDA indicates that the agency approved the new drug application, or NDA, submitted by Apellis Pharmaceuticals for the use of Syfovre for intravitreal use for the treatment of geographic atrophy secondary to age-related macular degeneration. Apellis Pharmaceuticals shares had been halted for trading this afternoon, pending news. Reference Link

14:50 EST 1Life Healthcare rallies, shares up 4% to $16.00 - On Wednesday, an Amazon.com (AMZN) spokesperson told Barron's that the company continues "work cooperatively" with the Federal Trade Commission as the agency review the pending 1Life Healthcare (ONEM) takeover. Amazon agreed to pay $18 per share for 1Life. The stock in afternoon trading is up 4% to $16.00. Reference Link

14:33 EST Apellis Pharmaceuticals trading halted, news pending

13:54 EST Allstate raises quarterly dividend 4.7% to 89c per share - Allstate Corporation announced that its board of directors has approved a quarterly dividend of 89c, which is an increase of 4c, or 4.7%, per share compared to last quarter. Allstate also declared the payment of quarterly preferred dividends. The quarterly dividend of 89c on each outstanding share of the corporation's common stock is payable in cash on April 3 to stockholders of record at the close of business on Feb. 28. "Allstate continues to provide excellent cash returns for our shareholders. The increase in our dividend this quarter demonstrates our commitment to returning capital to our shareholders, and is a sign of Allstate's continued financial strength," said Jess Merten, Allstate's CFO. "Over the past five years, Allstate has returned more than $15.5 billion to shareholders while continuing to invest in the future."

13:02 EST Baker Hughes reports U.S. rig count down 1 to 760 rigs - Baker Hughes reports that the U.S. rig count is down 1 from last week to 760 with oil rigs down 2 to 607, gas rigs up 1 to 151 and miscellaneous rigs unchanged at 2. The U.S. Rig Count is up 115 rigs from last year's count of 645 with oil rigs up 87, gas rigs up 27 and miscellaneous up 1. The U.S. Offshore Rig Count is down 1 to 17, up 5 year-over-year. The Canada Rig Count is down 2 from last week to 248, with oil rigs up 2 to 163, gas rigs down 4 to 85. The Canada Rig Count is up 28 rigs from last year's count of 220 with oil rigs up 28, gas rigs unchanged.

12:36 EST Amazon CEO Andy Jassy updates on return to office plans - Amazon CEO Andy Jassy said in a memo to employees that the company has concluded that "we should go back to being in the office together the majority of the time (at least three days per week). We made this decision at a s-team meeting earlier this week, and for a number of reasons (including the adjustments I know will be required for some of our employees), I wanted to share with you as early as I could even though we haven't worked out all the execution details yet. Of course, as there were before the pandemic, there will still be certain roles (e.g. some of our salespeople, customer support, etc.) and exceptions to these expectations, but that will be a small minority. We plan to implement this change effective May 1. It's not simple to bring many thousands of employees back to our offices around the world, so we're going to give the teams that need to do that work some time to develop a plan. We know that it won't be perfect at first, but the office experience will steadily improve over the coming months (and years) as our real estate and facilities teams smooth out the wrinkles, and ultimately keep evolving how we want our offices to be set up to capture the new ways we want to work. I know people will have questions about how this change will be implemented. We'll be finalizing those details in the coming weeks." Reference Link

12:00 EST Stem falls -15.6% - Stem is down -15.6%, or -$1.52 to $8.22.

12:00 EST RE/MAX Holdings falls -16.2% - RE/MAX Holdings is down -16.2%, or -$3.69 to $19.13.

12:00 EST Telephone and Data rises 18.9% - Telephone and Data is up 18.9%, or $2.10 to $13.23.

11:35 EST Peoples Bancorp raises dividend to 19c from 18c per share - The board of directors of Peoples Bancorp of North Carolina declared the company's regular cash dividend for the first quarter of 2023 in the amount of 19c per share. The first quarter cash dividend will be paid on March 15 to shareholders of record on March 3.

11:07 EST Microchip to invest $880M to expand SiC and Si capacity in Colorado - Microchip Technology announces plans to invest $880M to expand its silicon carbide, or SiC, and silicon, or Si, production capacity at its Colorado Springs, Colo. manufacturing facility over the next several years. "One significant phase of the expansion is to develop and upgrade its 50-acre, 580,000-square-foot Colorado Springs campus for increased SiC manufacturing for use in automotive/E-Mobility, grid infrastructure, green energy, and aerospace and defense applications. Working in conjunction with the Colorado Springs Chamber & Economic Development Corporation, the City of Colorado Springs and El Paso County also announce that Microchip was approved for state and local incentives of approximately $47M for the expansion," the company stated. President and CEO of Microchip Technology Ganesh Moorthy added, "Microchip Colorado Springs has a long history of partnering with the city and state and we applaud their continued support of our efforts to advance the semiconductor industry in the U.S. The CHIPS and Science Act is already making a positive impact on our business through the Investment Tax Credit and we are seeking capacity expansion grants for several of our semiconductor factories, including our Colorado Springs factory. We see a bright future in the region made possible by great partnerships, state and local incentives, and a strong local talented workforce."

11:03 EST Health Canada authorizes Moderna's mRNA-1273.214 in children, adolescents - Moderna announced that Health Canada has authorized the use of its Omicron-targeting bivalent COVID-19 booster vaccine, mRNA-1273.214 in children and adolescents 6 to 17 years of age. The authorizations are based on a 25 undefined booster dose for children ages 6 to 11 years old and a 50 undefined booster dose for adolescents 12 to 17 years old, each following a completed primary series of any of the authorized COVID-19 vaccines or a previous booster. The pediatric and adolescent authorization is based on clinical trial booster data for Moderna's original vaccine, Spikevax, which was administered to over a thousand participants in each cohort. The application described data from a 25 undefined booster dose administered to children ages 6 to 11 years old and a 50 undefined booster dose for adolescents 12 to 17 years old, following a completed primary series of the Moderna COVID-19 vaccine. In addition, the application included clinical trial data from a Phase 2/3 studying mRNA-1273.214.

10:29 EST Deere sees raw material costs getting more favorable throughout 2023

10:14 EST Deere: Farm income to still support replacing equipment

10:04 EST Bristol-Myers announces three-year results from Phase 3 CheckMate-274 trial - Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma. With a median follow-up of 36.1 months, adjuvant Opdivo continued to show improved disease-free survival, non-urothelial tract recurrence-free survival, distant metastasis-free survival and second progression-free survival compared to placebo across all-randomized patients and in patients whose tumor cells express PD-L1 greater than or equal to1%. These updated results will be featured in a late-breaking oral presentation at the American Society of Clinical Oncology 2023 Genitourinary Cancers Symposium from February 16-18, 2023. With three years of follow-up in the CheckMate -274 trial: DFS: Across all randomized patients, Opdivo more than doubled the average length of time patients lived without disease recurrence, demonstrating a median disease-free survival of 22.0 months compared to 10.9 months with placebo, a risk reduction of 29%. The risk reduction remained consistent with that observed at the primary analysis, with only a 1% change with an additional 25.7 months of minimum follow-up. In patients whose tumor cells express PD-L1 greater than or equal to1%, Opdivo extended the average length of time patients lived without disease recurrence more than six times compared to placebo, with median DFS of 52.6 months vs. 8.4 months with placebo, a 48% reduction in the risk of disease recurrence or death. NUTRFS: In all randomized patients, those treated with Opdivo showed a median NUTRFS, defined as the time that patients lived without disease recurrence outside of the bladder, ureters or renal pelvis, of 25.9 months compared to 13.7 months for placebo. In patients whose tumor cells express PD-L1 greater than or equal to1%, median NUTRFS was 52.6 months with Opdivo vs. 8.4 months with placebo. DMFS: Across all randomized patients, median DMFS, defined as the time that patients live without cancer spreading from the primary tumor to distant organs or lymph nodes, was 47.1 months with Opdivo vs. 28.7 months with placebo. Among patients whose tumor cells express PD-L1 greater than or equal to1%, median DMFS was not reached with Opdivo, compared to 20.7 months with placebo. PFS2: Median PFS2, defined as the time from randomization to disease progression after subsequent next-line systemic therapy, start of second subsequent next-line systemic therapy, or death, was 61.2 months for all-randomized patients treated with Opdivo compared to 47.1 months with placebo. In patients whose tumor cells express PD-L1 greater than or equal to1%, median PFS2 was not reached with Opdivo vs. 39.4 months with placebo. Safety: Grade 3-4 treatment-related adverse events occurred in 18.2% and 7.2% of patients in the Opdivo and placebo arms, respectively, consistent with the primary analysis.

10:00 EST RE/MAX Holdings falls -11.7% - RE/MAX Holdings is down -11.7%, or -$2.67 to $20.15.

10:00 EST Pediatrix Medical rises 12.7% - Pediatrix Medical is up 12.7%, or $1.91 to $16.98.

10:00 EST U.S. Cellular rises 16.6% - U.S. Cellular is up 16.6%, or $3.50 to $24.50.

09:50 EST Kite CEO Christi Shaw leaving Gilead at end of March - Christi Shaw has decided to leave Kite, a Gilead Company, effective end of March, Gilead announced in a statement. Daniel O'Day, Chairman and CEO of Gilead, "will work closely with Christi and the Kite leadership team over the next few weeks to ensure a smooth transition while a search is conducted for a new leader for Kite," it added.

09:47 EST American Axle falls -9.7% - American Axle is down -9.7%, or -97c to $9.08.

09:47 EST Kinsale Capital Group rises 7.0% - Kinsale Capital Group is up 7.0%, or $20.49 to $312.50.

09:47 EST HubSpot rises 13.7% - HubSpot is up 13.7%, or $49.67 to $411.60.

09:33 EST Stryker's Q Guidance System for cranial applications receives FDA clearance - Stryker announced that its Q Guidance System with Cranial Guidance Software received 510(k) clearance from the U.S. Food and Drug Administration. The Q Guidance System is an image-based planning and intraoperative guidance system designed to support cranial surgeries, the firm says. Recently launched in September 2022, the Q Guidance System for spinal applications is currently available on the market. "The FDA clearance of Stryker's Q Guidance System with Cranial Guidance Software is a key milestone, which will help lead the transformation of cranial navigation and surgery," said Robbie Robinson, president of Stryker's Spine division. "Our robust pipeline of iterative launches reinforces our commitment to making industry-leading investments focused on providing advanced navigation products and differentiated technologies that our surgeon customers have come to expect."

09:29 EST Zynex set to join the MSCI USA Small Cap Index - Zynex announced that it is set to join the MSCI USA Small Cap Index according to the list of additions posted by MSCI on February 9. Inclusion in the index will take effect after the market close on February 28.

09:21 EST Cazoo to sell German subscription business Cluno to ViveLaCar - Cazoo has agreed to sell its German subscription business, Cluno, to ViveLaCar and The Platform Group GmbH & Co. KG. The financial terms of the transaction were not disclosed, the total portfolio includes several thousand cars in the German market. The disposal concludes Cazoo's withdrawal from the German market as part of its strategy to focus exclusively on the UK market. The agreement includes 100% of the capital and voting rights of the company Cluno and the Cluno brand along with the associated assets. All employees of Cluno will transfer to ViveLaCar GmbH as part of the agreement. Following this transaction, together with previously announced sales of other businesses and assets in Europe, the withdrawal of Cazoo from mainland Europe is now largely complete.

09:06 EST Amarin urges shareholders to vote against Sarissa proposals - The Amarin Corporation Board of Directors issued the following statement reiterating to shareholders its recommendation to vote on the WHITE proxy card "AGAINST" all of Sarissa's proposals ahead of the General Meeting of Shareholders, which is scheduled to be held on February 28, 2023. Shareholders of record as of January 23, 2023, will be entitled to vote at the meeting. For ADS holders, the deadline to submit votes is 3 PM GMT on February 22, 2023, and for holders of ordinary shares, the deadline is 3 PM GMT on February 24, 2023. The company said, "The Amarin Board has one critical message for our shareholders: Amarin is at an inflection point, where upcoming pricing and reimbursement negotiations and decisions will chart the future for the Company, including ensuring M&A is a viable option. Our refreshed Board are the change agents the Company needs and have actively positioned the business to turn Amarin around and drive near- and long-term value. As leading independent proxy advisory firms Institutional Shareholder Services and Glass Lewis & Co recognized in their vote recommendations for Amarin's WHITE proxy card "AGAINST" Sarissa's proposals, the new and refreshed Board has already made significant changes over the last 18 months. Meanwhile, Sarissa has failed to make a compelling case for change. ISS and Glass Lewis's recommendations are important third party endorsements that Amarin has the RIGHT strategy, RIGHT team and RIGHT Board to drive near- and long-term value... The Amarin Board has been and continues to be 100% focused on advancing all of our shareholders' best interests. Sarissa, on the other hand, purposefully provides shareholders with misinformation as part of its transparent attempt to do anything to get on the Board. Sarissa is only focused on serving its own self-interest at the expense of all Amarin shareholders. If Sarissa cannot be trusted to provide shareholders with the truth, why should it be trusted as a steward of shareholder value creation? The current Amarin Board is best equipped to guide the NEW Amarin and maximize shareholder value. We strongly urge all shareholders to consider what is at stake and vote "AGAINST" Sarissa's harmful proposals on the WHITE proxy card."

09:03 EST Privia Health enters Connecticut with Community Medical Group - Privia Health announced its partnership with Community Medical Group, CMG, to launch Privia Quality Network of Connecticut, PQN CT, as the largest Clinically Integrated Network, CIN, in Connecticut. The CIN comprises approximately 1,100 multi-specialty providers, including more than 430 primary care providers, caring for patients in over 450 practice locations. Privia Health will be the majority owner of PQN CT, which contracts with Commercial and Medicare payers covering approximately 180,000 patient lives attributed to value-based care arrangements. "CMG is the largest independent physician network in Connecticut, and has a stellar reputation for delivering high-quality patient care while managing total medical costs through its network of primary care and specialist providers," said Privia Health CEO Shawn Morris. "Our partnership with CMG to form PQN CT represents another significant step toward Privia's goal of building a national network of primary and specialty care providers, and we are excited to continue to expand their presence across the state. This partnership reaffirms Privia Health's ability to replicate our highly differentiated and flexible operating model with new anchor partners across the U.S."

08:48 EST Penn Entertainment completes Barstool Sports acquisition for $388M - Penn Entertainment completed its previously announced acquisition of Barstool Sports after previously acquiring a 36% stake of Barstool Sports in February 2020. Penn has acquired the remaining interest in Barstool Sports for approximately $388M. "We are extremely pleased to welcome Barstool Sports fully into the PENN Entertainment family," said PENN Entertainment CEO and President, Jay Snowden. "Barstool is a proven, powerful media brand with an authentic voice and vast, loyal audience that provides us with a strong top of funnel for new customer acquisition and organic cross-selling opportunities across our growing interactive division. Barstool, combined with theScore's reach and highly engaged user base, creates a massive digital footprint and ecosystem that will serve to propel Barstool Sportsbook and our uniquely integrated media and gaming business. Further, the Barstool Sportsbook will greatly benefit from the upcoming migration to our proprietary technology stack, a move that will significantly enhance the overall product offering and deliver meaningful upside."

08:38 EST Cass Information Systems names Martin Resch CEO - Cass Information Systems announced that Martin Resch, president and COO, has been named president and CEO, effective April 18 and will join the board of directors at that time. Resch has been Cass's president and COO since February 2022 and will succeed Eric Brunngraber in the role of CEO. Brunngraber, who has served as CEO since 2008, will become executive chairman, effective April 18.

08:34 EST Ondas' Airobotics receives additional orders for drone infrastructure services - Ondas Holdings announced that its wholly-owned subsidiary, Airobotics, has received an order for continued services from a semiconductor chip manufacturer. Airobotics' aerial data Infrastructure, Optimus System, has been installed at a large chip fabrication facility in Israel, providing autonomous drone services since 2016. The semiconductor chip manufacturer will continue to use data and analytics collected from the Optimus System in addition to its remote monitoring services to ensure security and project safety within one of its most important semiconductor fabrication plants. The technology will also be used for construction project management within new fabrication plants, providing progress monitoring, survey, and geo-visual data and analytics to project managers and other stakeholders.

08:33 EST Sarepta announces first patient dosed in SRP-9003-102 study - Sarepta announced that the first patient has been dosed in Study SRP-9003-102. Also known as VOYAGENE, Study 9003-102 is a phase 1 study of SRP-9003 for the treatment of limb-girdle muscular dystrophy Type 2E/R4. VOYAGENE is a U.S.-only study enrolling ambulant patients aged 18 years or older and non-ambulant patients, ages 4-50 years, using clinical process SRP-9003 material.

08:32 EST Flowr Corporation requests to delist from TSX Venture Exchange - The Flowr Corporation announces that in connection with the closing of its previously announced sale transaction under the Companies' Creditors Arrangement Act, all of the former officers and directors of the Company have resigned and the Court has expanded the powers of Ernst & Young Inc., which acts as the Court appointed Monitor under the CCAA Proceedings in order to oversee the remaining activities in the CCAA Proceedings including any distribution to creditors and the winding down of operations. On account of the Company having no operating business and having sold substantially all of its assets, as well as the resignation of its management and board of directors, the CCAA Monitor has requested that the common shares of the Company be delisted from the TSX Venture Exchange.

08:25 EST American Axle falls 7% to $9.35 after Q4 EPS misses estimates

08:12 EST Jasper Therapeutics announces follow-up data from briquilimab study - Jasper Therapeutics announced that new follow-up data from Jasper's investigator-sponsored study of briquilimab as a conditioning agent in the treatment of Fanconi Anemia were presented in a poster presentation at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR taking place in Orlando, Florida. The study is a Phase 1/2 clinical trial utilizing briquilimab to treat FA patients in bone marrow failure requiring allogeneic transplant with non-sibling donors. The objective of the study is to develop cell therapy, which enables blood and immune reconstitution in FA patients with decreased toxicity, by using briquilimab as a part of conditioning which eliminates the need for busulfan chemotherapy or total body irradiation. In the follow-up data series presented, 100% total donor chimerism was achieved through six months for the first patient and at three months for the second patient. Neutrophil engraftment was reached on day 11 for both patients and platelet engraftment was achieved on days 14 and 9 for the first and second patient, respectively. Briquilimab was cleared by day 9 after dosing in both patients and no treatment-related adverse events or toxicities were observed. No veno-occlusive disease or graft-versus-host disease has been observed. Initial data from this study were previously presented at the annual conference of the Inborn Errors Working Party, a research group of the European Society of Blood and Marrow Transplantation, in September 2022. Allogeneic hematopoietic stem cell transplantation offers a potential cure for many diseases, including FA. It is also the only proven treatment for the bone marrow failure that occurs in a majority of patients with FA. However, current allo-HSCT protocols require conditioning with genotoxic chemotherapy and/or irradiation leading to toxicities, including mucositis, end organ damage, infertility and secondary malignancies. Furthermore, allo-HSCT can also be complicated by graft-versus-host disease and serious infections. Patients with FA are particularly vulnerable to such toxicities due to their inherent inability to DNA repair defects.

08:09 EST Twin Vee PowerCats says LFG Marine to attend Freedom Boat Club Forum - Twin Vee PowerCats announced that it will be attending Freedom Boat Club's Freedom Forum 2023 from February 19th to 24th in Cape Coral, Florida. Twin Vee will showcase its new 220 Center Console from its new boat brand, LFG Marine, and offer sea trials to the more than 600 franchisees and guests attending Freedom Boat Club's 5-day event.

08:07 EST PPL Corp. reaffirms $12B of planned infrastructure investments from 2023-2026 - PPL also reaffirmed its planned infrastructure investments, targeting $12B in improvements from 2023 to 2026 to strengthen grid reliability and resiliency and economically replace aging coal generation with reliable, least-cost and clean energy sources. These investments are expected to result in 5.6% average annual rate base growth through 2026, with greater than 7% rate base growth in the back half of the plan. Also as outlined on Jan. 11, PPL has raised its target for annual operation and maintenance savings to at least $175M by 2026. The expected savings will be driven largely by transmission and distribution operations as PPL continues to deploy scalable technologies and data science across its utility portfolio. The company's plan also continues to support a balance sheet that is among the best in the U.S. utility sector, supporting the company's capital investment plan without the need to issue equity through at least 2026. PPL's credit profile also reflects a projected Funds from Operations/Cash Flow from Operations to debt ratio of 16% to 18% throughout the planning period.

08:05 EST Jasper Therapeutics presents data from Phase 1 study on briquilimab - Jasper Therapeutics announced new positive Phase 1 data on briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia or myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplant. The data are being featured in two oral presentations and one poster presentation at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. The presentations further support the differentiated clinical profile of briquilimab and its potential as a safe and efficacious conditioning agent for HCT therapies. Specifically, the data show that a conditioning regimen of briquilimab plus Flu/TBI led to successful engraftment of donor blood stem cells in the patients treated. The conditioning regimen was well-tolerated, with no infusion toxicities observed and no briquilimab-related serious adverse events. "As we focus the development of briquilimab on treating chronic mast cell diseases and as a conditioning agent for stem cell transplants addressing rare diseases, we believe that the data presented at the Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR provides the additional mechanistic and clinical proof-of-concept rationale for its mechanism of targeting c-Kit," said Ronald Martell, President and Chief Executive Officer of Jasper. "The data continues to show a favorable safety profile and a consistent and predictable pharmacokinetic/ pharmacodynamic profile, making briquilimab potentially amenable to various indications. We demonstrated that briquilimab exhibits on-target effects on HSC depletion when combined with Flu/TBI and enables full donor myeloid chimerism, resulting in promising disease resolution in older patients with AML or MDS. We look forward to continuing the development of briquilimab and to exploring its long-term potential to become the leading antibody targeting c-Kit."

08:04 EST Lumine Group to acquire Titanium Software, terms not disclosed - Lumine Group entered into a binding agreement to acquire Titanium Software Holdings. Titanium provides flexible and powerful platforms for telecommunication and government organizations to build out global carrier networks and secure private communication services. Closing is expected to occur in the first quarter of 2023, subject to satisfaction of customary conditions to closing as set forth in the acquisition agreement. The company said, "Titanium's core focus is signaling, routing, subscriber data management, and security, allowing network operators to simplify and virtualize their core network functions and interoperate legacy and next-gen networks. Founded in 1998 in Lowell, Massachusetts, today, Titanium's solutions can be found in over 85 countries across the globe, counting tier-1 communication service providers as part of their group of valued customers."

08:02 EST Genius Sports enters data distribution agreement with XFL - The XFL announced that Genius Sports has been named the Official Betting Data Distribution Partner and Free-to-Play Provider of the League. Genius Sports has been granted the exclusive rights to distribute official data from every XFL game to its global network of media and betting partners. Sportsbooks will be provided with the fastest, most accurate feed of XFL data, while brands and advertisers will be able to access official XFL data through the Genius Marketing Suite, an all-in-one fan engagement platform. To help the XFL expand its digital audience and drive fan engagement levels, Genius Sports has built a new "XFL Pick'Em" game. This free-to-play game asks fans to predict the outcome of upcoming XFL matchups, including various proposition bets related to games, players, and teams. To gamify the experience, fans are asked to bet with football tokens, creating parlays to increase their potential score and improve their ranking on the league-wide leaderboard. Weekly winners will be eligible for a variety of prizes, including XFL Shop gift cards, and a grand prize winner will receive a trip for two to the 2023 XFL Championship Game.

08:02 EST Vital Farms launches new relationship with Dot Foods - Vital Farms has kicked off a new relationship with Dot Foods, the largest food industry redistribution company in North America, to make our Vital's "eggs-essible" to their network of 5,200 distributors across all 50 states. This marks two firsts -the first egg brand Dot Foods has ever stocked and redistributed nationally, and this is the first time ever Vital's pasture-raised eggs are available for national foodservice distribution. "People are craving more ethical food when dining out. Our new relationship with Dot Foods will help more people enjoy high-quality eggs at restaurants and other places away from home," said Ash Idais, Senior Director, Foodservice, Vital Farms. "In the early days of Vital Farms, our founder hand-delivered eggs to Austin restaurants from the back of his Subaru. Fast forward 15 years-it's exciting to now have vendors like Dot helping us bring more ethical food to tables across the country."

07:42 EST Raytheon Technologies awarded $135M contract for propellers for C-130 - The U.S. Air Force Life Cycle Management Center recently contracted Raytheon Technologies' Collins Aerospace business to continue producing new, advanced propellers for C-130 aircraft. The $135M contract will allow Collins to manufacture and support new NP2000 propeller systems, including the electronic control system and spares.

07:33 EST OpGen announces exercise of all prefunded warrants - OpGen announced that all of the prefunded warrants that were issued in its public offering that closed on January 11, 2023 have been exercised in full. In light of the exercise of the 2,265,000 prefunded warrants issued in the public offering, the Company has issued an equal number of common shares, resulting in a total number of shares outstanding as of February 15, 2023 of 5,483,919. As of February 16, 2023, no prefunded warrants remain outstanding.

07:32 EST Permian Basin Royalty Trust declares monthly cash distribution of 4.14c per unit - Argent Trust Company, as Trustee of the Permian Basin Royalty Trust, declared a cash distribution to the holders of its units of beneficial interest of 4.1356c per unit, payable on March 14 to unit holders of record on February 28. This month's distribution increased from the previous month as the result of primarily an increase in production of both oil and gas offset by a decrease in pricing for oil and an increase in gas pricing for the Waddell Ranch and Texas Royalty Properties during the month of December. Also, a decrease in CAPEX for the Waddell Ranch as year-end activity to complete the 2022 budgeted projects increased the amount of NPI for the month of December.

07:11 EST Luxor Capital Group releases presentation to fellow Ritchie Bros shareholders - Luxor Capital Group, as the manager of funds owning 4.7M shares of Ritchie Bros. Auctioneers Incorporated (RBA), representing approximately 4.2% of the Company's outstanding shares, announced that it has released a presentation to RBA shareholders detailing its reasons for why RBA shareholders should oppose the proposed merger with IAA (IAA). "The IAA Merger is the result of a deeply flawed and manipulated process led by a management team with no experience in large scale M&A and caught up in the fever of deal-making at any cost. RBA reacted to the extraordinary shareholder opposition to its value-destroying merger with baffling intransigence and issued a grossly mispriced security to an activist fund that will transfer value away from RBA shareholders," said Doug Snyder, President of Luxor. Luxor outlines why it believes that the IAA Merger is an extremely value destructive error by the RBA board of directors that must be corrected by a NO vote: A deeply flawed and manipulated process. Almost a month after the IAA deal price was agreed to and two weeks before the deal was announced, at a time when RBA was materially out-performing expectations, RBA manipulated the fairness opinion outcome by introducing a new forecast well below its prior set of projections and required its advisors to rely on these low-ball estimates for its valuation. Using the same DCF assumptions as those used by RBA's own advisors' applied to the original set of projections, shows that the deal did not work.... Shareholders need to vote NO on a deal based on manipulated projections that do not reflect the reality of either company's business. RBA has incredible standalone prospects. RBA is an unusually attractive and deeply undervalued business with a dominant market position built over many decades. The Company remains in the early innings of monetizing its market position as it unlocks potential revenue streams, akin to what countless marketplaces have done before it. Again, using RBA's own advisors' DCF assumptions on the mid-point of the evergreen metrics, with capex ~25% above historical levels, the business is worth ~$111 per share at the mid-point on a standalone basis - and we believe far more - as the business continues to out-perform as evidenced by the Q4 results. The combination will destroy billions in RBA shareholder value. As highlighted by the 18% stock drop on the day of announcement, the plurality of negative sell-side opinions, and the continued underperformance of RBA shares relative to the NASDAQ of greater than15%, the deal clearly lacks strategic rationale. In response, the Company has repeatedly shifted its narrative, first citing diversification, then making the focus RBA's yards being used for IAA, then moving on to fanciful revenue synergies, and now squarely resting their case on the potential satellite yard benefit for RBA... We do not think a greater than $7 billion acquisition is necessary for what the Company can achieve on a standalone basis at a cost of ~$30 million or less. RBA responded to opposition to the IAA Merger by punishing RBA shareholders. The proxy statement made it abundantly clear that the RBA Board and management are not open to feedback and wish to force the deal through by any means necessary.

07:07 EST Shaw Communications suspends dividend reinvestment plan - Shaw suspended its DRIP effective February 13, 2023. Shaw shareholders who have been participating in the DRIP will receive: each whole Class B Non-Voting Participating Share or Class A Participating Shares to which they were entitled under the DRIP; and a cash payment for any fractional shares previously held in the DRIP. Any future dividends paid by Shaw will be received by former DRIP participants in cash.

07:03 EST Molekule to showcase products, services at IAQA meeting - Molekule Group will feature its patented and proprietary suite of products and services at the 2023 Indoor Air Quality Association Annual Meeting and showcase its leaders' expertise on a variety of indoor air quality management and deployment topics. This conference brings together the world's leaders in indoor air quality to discuss topics such as chemical contaminants, infectious diseases, mold, bacteria, and more. The IAQA Annual Meeting will take place February 19-22, 2023 at the Marriott Downtown in Austin, TX. Methodology for Determining "Real-World" Portable Air Cleaner Performance in Small and Large Settings: About this session: Effectiveness of improving IAQ with portable air sanitization devices are dependent upon laboratory-based performance of the purifier and the unique environment in which the purifier will operate. The recent recommendation of the Lancet Covid-19 Commission recognizes this reality and recommends that more than just laboratory testing is required to quantify device performance in the real world. Testing with active pathogens in real world settings is time consuming and expensive. Development of a convenient testing methodology which produces results accurate enough to ensure meaningful pathogen reduction data is desirable. Fine particle reduction testing using a high-performance particle detector in a large, densely populated room was compared with reduction in a smaller, medical exam room. Fine particle reduction of 61-76% was achieved in the large setting and 68-79% in the small setting. The fine particle reduction data combined with SARS CoV-2 information and human factors estimates such as inhaled volume and breathing rate were used in the Wells Riley infectious probability model to estimate performance level. The calculated reduction in infection probability for the small setting was 63% and for the large setting 70%. The data suggest the use of fine particle arrestance testing can provide meaningful insight for the effective deployment of portable air purifiers in various settings. Digital IAQ Management: Integrating IAQ Sensors and Air Quality Data Insights with Air Filtration: About this session: Given advances in indoor air quality monitoring technology, coupled with increasing pressure on commercial spaces to provide not only clean indoor air but also peace of mind through air quality data transparency, the demand to modernize organizational approaches to the monitoring, measurement, and management of indoor air quality is growing. This presentation will explore how Digital IAQ Management and Integration of IAQ sensors on Air Sanitization can enable organizations to support improved employee and customer health, management of seasonal/climate-specific environments, healthy building and business continuity initiatives, and maintain overall indoor air quality.

06:56 EST Aecom chosen as program manager for Fair Park capital projects program in Texas - Aecom announced that it has been selected by Fair Park First to provide program management services for major capital improvements to Fair Park, a 277-acre, cultural and entertainment complex in the heart of Dallas, Texas. AECOM will support Fair Park First's capital projects to deliver outcome-driven solutions and a lasting legacy through enhancements that create and integrate park facilities, preserve historically significant venues, and revitalize the park as a destination within the region and beyond.

06:36 EST Citizens Financial announces $1.15B increase to share repurchase program - Citizens Financial Group announced that its board of directors has increased the capacity of the company's common share repurchase program by an additional $1.15B. This is incremental to the $850M of capacity remaining as of December 31, 2022 under the prior June 2022 authorization, of which $400M will be utilized during first quarter 2023.

06:32 EST AdvanSix sees FY23 CapEx $110M-$120M - "With our diverse product portfolio, continued strong agricultural and fertilizer industry fundamentals and the resilience of our business model, AdvanSix is well positioned for another year of differentiated performance in 2023. While we anticipate the challenges of an uncertain environment to impact several end applications within our nylon and chemical intermediates product lines, we remain confident in our demonstrated ability to perform through various business and macroeconomic cycles. We have structurally improved the earnings power of this business and are targeting a return to higher plant production rates in 2023 to complement our strong commercial performance. Our healthy balance sheet will serve us well and continues to support our ability to deploy capital and maximize shareholder value," said CEO Erin Kane.

06:15 EST BIT Mining reports crypto assets of $15M in aggregate - As of December 31, 2022, the Company had cryptocurrency assets of $15M in aggregate, which is the U.S. dollar equivalent of 289 BTC, 4,845 ETH, 42.8 million DOGE and various other cryptocurrency assets, including those generated from its mining pool and cryptocurrency mining businesses.

06:04 EST Schwazze opens R. Greenleaf Paseo in New Mexico - Schwazze announces the grand opening of its adult-use dispensary, R.Greenleaf Paseo, opening on Saturday, February 18, 2023. The new store, open to both recreational and adult use consumers, is located at 8150 Louisiana BLVD NE in Albuquerque. Store operating hours are 9a to 10p Monday through Saturday; 9a to 8p on Sunday. The R.Greenleaf Paseo store opening continues the intentional expansion throughout the state of New Mexico and comes on the heels of a total of six additional R.Greenleaf store openings since Schwazze's acquisition of the retail banner one year ago in February 2022. This brings R.Greenleaf's total number of New Mexico retail dispensaries to 17.

05:58 EST Payoneer Global receives UK E-Money license from Financial Conduct Authority - Payoneer has received, via its subsidiary, Payoneer Payment Services UK Ltd, its Electronic Money License from the United Kingdom's Financial Conduct Authority. The license is a key requirement for digital financial institutions to continue operating in the UK and will allow Payoneer to keep providing its full suite of services to UK-based businesses. The FCA authorisation demonstrates Payoneer's commitment to the UK market as it seeks to continue providing regulated financial solutions. The license enables Payoneer to carry on empowering UK businesses to grow globally in the digital global economy. Payoneer will also look to grow its footprint in the UK, seeking to help more businesses navigate the world of global digital commerce.

05:57 EST NatWest Group to commence GBP 800M buyback program - The company said it intends to commence an ordinary share buyback program of up to GBP 800 million in the first half of 2023, taking total distributions deducted from capital in the year to GBP 5.1 billion, or 53 pence per share.